Page 86 - 《中国药房》2021年20期

[21] GAO L，LI S C. Modelled Economic evaluation of ni- pembrolizumab plus chemotherapy for newly diagnosed
volumab for the treatment of second-line advanced or meta- metastatic non-small-cell lung cancer：a cost-effectiveness
static squamous non-small-cell lung cancer in Australia analysis[J]. Transl Lung Cancer Res，2020，9（5）：1770-
using both partition survival and Markov models[J]. Appl 1784.
Health Eco Hea，2019，17（3）：371-380. [31] 刘国恩，胡善联，吴久鸿，等.中国药物经济学评价指南
[22] INSINGA R P，VANNESS D J，FELICIANO J L，et al. 2020：中英双语版[M].北京：中国市场出版社，2020：
Cost-effectiveness of pembrolizumab in combination with 55-56
chemotherapy versus chemotherapy and pembrolizumab [32] RUI M，WANG Y，FEI Z，et al. Will the Markov model
monotherapy in the first-line treatment of squamous and partitioned survival model lead to different results：a
non-small-cell lung cancer in the US[J]. Curr Med Res review of recent economic evidence of cancer treat-
Opin，2019，35（7）：1241-1256. ments[J]. Expert Rev Pharmacoecon Outcomes Res，2021，
[23] WAN X，LUO X，TAN C，et al. First-line atezolizumab in 21（3）：373-380.
addition to bevacizumab plus chemotherapy for metasta- [33] CARO J J，BRIGGS A H，SIEBERT U，et al. Modeling
tic，nonsquamous non-small cell lung cancer：a United good research practicesoverview：a report of the ISPOR-
States-based cost-effectiveness analysis[J]. Cancer，2019， SMDM modeling good research practices task force1[J].
125（20）：3526-3534. Med Decis Making，2012，32（5）：667-677.
[24] ZENG X，WAN X，PENG L，et al. Cost-effectiveness ana- [34] BECA J，HOCH J S. Exploring the impact of structural un-
lysis of pembrolizumab plus chemotherapy for previously certainty in partitioned survival models for oncology[J].
untreated metastatic non-small cell lung cancer in the USA Value Health，2014，17（3）：A205-A206.
[J]. BMJ Open，2019，9（12）：e31019. [35] DEGELING K，FRANKEN M D，MAY A M，et al. Ma-
[25] DING D，HU H，LIAO M，et al. Cost-effectiveness analy- tching the model with the evidence：comparing discrete
sis of atezolizumab plus chemotherapy in the first-line event simulation and state-transition modeling for time-to-
treatment of metastatic non-squamous non-small cell lung event predictions in a cost-effectiveness analysis of treat-
cancer[J]. Adv Ther，2020，37（5）：2116-2126. ment in metastatic colorectal cancer patients[J]. Cancer
[26] JIANG Y，WANG X. Cost-effectiveness analysis of pem- Epidemiol，2018，57：60-67.
brolizumab plus standard chemotherapy versus chemo- [36] NADAL E，MASSUTI B，DOMINE M，et al. Immunothe-
therapy alone for first-line treatment of metastatic non- rapy with checkpoint inhibitors in non-small cell lung can-
squamous non-small-cell lung cancer in China[J/OL]. Eur cer：insights from long-term survivors[J]. Cancer Immu-
J Hosp Pharm，2020：1-6[2021-03-02]. https：//ejhp.bmj. nol Immunother，2019，68（3）：341-352.
com/content/early/2020/07/31/ejhpharm-2020-002208.alerts. [37] BRIGGS A，SCULPHER M，CLAXTON K. Decision
DOI：10.1136/ejhpharm-2020-002208. modelling for health economic evaluation[M]. Oxford：
[27] LIN S，LUO S，ZHONG L，et al. Cost-effectiveness of Oxford University Press，2008：95-97.
atezolizumab plus chemotherapy for advanced non-small- [38] PHILLIPPO D M，ADES A E，DIAS S，et al. NICE DSU
cell lung cancer[J]. Int J Clin Pharm，2020，42（4）：1175- technical support document 18：methods for population-
1183. adjusted indirect comparisons in submission to NICE[S].
[28] ROTHWELL B，KIFF C，LING C，et al. Cost-effective- 2016-12.
ness of nivolumab in patients with advanced，previously [39] CARO J J，ISHAK K J. No head-to-head trial：simulate
treated squamous and non-squamous non-small-cell lung the missing arms[J]. Pharmacoeconomics，2010，28（10）：
cancer in England[J]. Pharmacoeconomics Open，2020，5： 957-967.
251-260. [40] PHILLIPPO D M，DIAS S，ADES A E，et al. Multilevel
[29] WAN N，ZHANG T T，HUA S H，et al. Cost-effectiveness network meta-regression for population-adjusted treat-
analysis of pembrolizumab plus chemotherapy with PD-L1 ment comparisons[J]. J R Stat Soc A Stat，2020，183（3）：
test for the first-line treatment of NSCLC[J]. Cancer Med， 1189-1210.
2020，9（5）：1683-1693. （收稿日期：2021-03-10 修回日期：2021-09-11）
[30] WU B，LU S. The effect of PD-L1 categories-directed （编辑：孙 冰）

·2508 · China Pharmacy 2021 Vol. 32 No. 20 中国药房 2021年第32卷第20期